ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "antiphospholipid syndrome"

  • Abstract Number: 0108 • ACR Convergence 2024

    Phenotypic Characterization of Patients with IgM Antibodies in Antiphospholipid Syndrome (APS)

    Fernanda Oliveira de Andrade Lopes1, Andreia Coimbra Sousa2, Massimo Radin3, Gustavo Balbi4, Irene Cecchi3, Savino Sciascia5, Flavio Victor Signorelli6 and Danieli Andrade2, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 2University of São Paulo, São Paulo, SP, Brazil, 3University of Turin, Turin, Italy, 4Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil, 5University of Turin, Torino, Turin, Italy, 6Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil

    Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although the presence of lupus anticoagulant…
  • Abstract Number: 0124 • ACR Convergence 2024

    Sexual Health Challenges in Primary Antiphospholipid Syndrome: Exploring Prevalence and Clinical Correlates

    Jonathan Campos-Guzmán1, María Espinosa-León2, Iris Paola García Herrera1, Iris Jazmín Colunga Pedraza3, Mariel Martínez-Ruiz1, Ana Barrera-Vargas4, Guillermo Guaracha Basañez5 and javier Merayo Chalico6, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 4Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Federal District, Mexico, 5Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirón", Mexico City, Mexico, 6Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, CDMX, Mexico

    Background/Purpose: Antiphospholipid syndrome (APS) is a systemic thromboinflammatory disease with various forms of presentation. There is limited information on sexual function in patients with APS,…
  • Abstract Number: 1240 • ACR Convergence 2024

    Living with Antiphospholipid Antibodies: A Photovoice Exploration

    Francesca Cardwell1, Susan J. Elliott2, Paul S. Gibson3, Nancy Soliman4, Leslie Skeith4, Ann E. Clarke5 and Megan Barber5, 1University of Waterloo, Burlington, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3University of Calgary, Calgary, AB, Canada, 4University of Calgary, Calgary, ON, Canada, 5Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

    Background/Purpose: The diverse manifestations of antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPLs) exert substantial but poorly understood impacts on the lives of those affected. This…
  • Abstract Number: 0109 • ACR Convergence 2024

    Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Rohan Willis1, Anne Tebo2, Leslie Skeith3, Nina Kello4, H Michael Belmont5, Paul Fortin6, Guilherme Ramires de Jesús7, David Branch8, Michelle Petri9, Jason Knight10, Reyhan Kose Cobanoglu11, Maria Laura Bertolaccini12, Hannah Cohen13, Robert Roubey14, Doruk Erkan15 and Danieli Andrade16, and on behalf of APS ACTION, 1University of Texas Medical Branch, Galveston, TX, 2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 3University of Calgary, Calgary, ON, Canada, 4Northwell Health, Brooklyn, NY, 5NYU School of Medicine, New York, NY, 6Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 7Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 8University of Utah and Intermountain Healthcare, Salt Lake City, UT, 9Johns Hopkins University School of Medicine, Timonium, MD, 10University of Michigan, Ann Arbor, MI, 11Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, 12King's College London, London, United Kingdom, 13University College London Hospitals NHS Foundation Trust, London, United Kingdom, 14Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 15Hospital for Special Surgery, New York, NY, 16University of São Paulo, São Paulo, SP, Brazil

    Background/Purpose: Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are characterized by heterogenous clinical presentations, driven by autoantibodies; patients with SLE develop APS more often…
  • Abstract Number: 0125 • ACR Convergence 2024

    Electronic Health Record Rule-Based Computable Phenotype of Antiphospholipid Syndrome

    Emily Balczewski1, Amala Ambati2, Wenying Liang1, Jacqueline Madison1, Yu Zuo1, Karandeep Singh3 and Jason Knight1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Toledo, OH, 3University of California -- San Diego, San Diego, CA

    Background/Purpose: Electronic health record (EHR) data provide a widely available, inexpensive, and information-rich tool that is underutilized in the research of rare diseases like antiphospholipid…
  • Abstract Number: 1267 • ACR Convergence 2024

    Antiphospholipid Antibody-related Clinical Manifestations Presenting During Childhood versus Adulthood: Descriptive Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Jheel Pandya1, Danieli Andrade2, Ann E. Clarke3, Maria Tektonidou4, Vittorio Pengo5, Massimo Radin6, Jose Pardos-Gea7, Nina Kello8, Diana Paredes-Ruiz9, Mª Angeles Aguirre-Zamorano10, H Michael Belmont11, Paul Fortin12, Flavio Victor Signorelli13, TATSUYA ATSUMI14, Zhuoli Zhang15, Maria Efthymiou16, David Branch17, Giulia Pazzola18, Angela Tincani19, Ali Duarte-Garcia20, Esther Rodriguez-Almaraz21, Michelle Petri22, Ricard Cervera23, Bahar Artim Esen24, Guillermo Pons-Estel25, Hui Shi26, Yu Zuo27, Rohan Willis28, Pierluigi Meroni29, Robert Roubey30, Maria Laura Bertolaccini31, Hannah Cohen32 and Doruk Erkan1, and on behalf of APS ACTION, 1Hospital for Special Surgery, New York, NY, 2University of São Paulo, São Paulo, SP, Brazil, 3Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 4National and Kapodistrian University of Athens, Athens, Greece, 5Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 6University of Turin, Turin, Italy, 7Vall d'Hebron University Hospital, Barcelona, Spain, 8Northwell Health, Brooklyn, NY, 9Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, 10IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, 11NYU School of Medicine, New York, NY, 12Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 13Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 14Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 15Peking University First Hospital, Beijing, China, 16University College London, London, United Kingdom, 17University of Utah and Intermountain Healthcare, Salt Lake City, UT, 18Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, 19ASST Spedali Civili-University of Brescia, Brescia, Italy, 20Mayo Clinic, Rochester, MN, 21Hospital Universitario 12 de Octubre, Madrid, Spain, 22Johns Hopkins University School of Medicine, Timonium, MD, 23Hospital Clinic de Barcelona, Barcelona, Spain, 24Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 25CREAR, Rosario, Argentina, 26Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic), 27University of Michigan, Ann Arbor, MI, 28University of Texas Medical Branch, Galveston, TX, 29IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 30Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 31King's College London, London, United Kingdom, 32University College London Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: APS ACTION Registry studies long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic autoimmune rheumatic diseases. Given autoimmune diseases present differently in…
  • Abstract Number: 0110 • ACR Convergence 2024

    Binding Characteristics of Patient Clusters Among Anticardiolipin and Anti-β2-Glycoprotein I ELISA and Non-ELISA Assays: A Survey by the Association of Medical Laboratory Immunologists

    Rohan Willis1, Vijaya Murthy2, Karen Roye-Green3, Amy Thees4, May Choi5, Ken Dier6, Marvin Fritzler7, Susan Fink8, Vijayalakshmi Nandakumar9, Melissa Snyder10 and Anne Tebo11, and the Association of Medical Laboratory Immunologists, 1University of Texas Medical Branch, Galveston, TX, 2University of Texas Medical Branch (UTMB), League City, TX, 3University of the West Indies, Kingston, Jamaica, 4Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, 5University of Calgary, Calgary, AB, Canada, 6Corgenix, Broomfield, CO, 7Mitogen Diagnostics Corp, Calgary, AB, Canada, 8Clinical Immunology Laboratory, University of Washington Medical Center, Seattle, WA, 9ARUP/University of Utah, Salt Lake City, UT, 10Clinical Biochemistry and Immunology, Antibody Immunology Laboratory, Mayo Clinic, Rochester, MN, 11Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

    Background/Purpose: We have recently shown that anti-phospholipid (APL) assays of varying methodology demonstrate comparable analytical performance despite variable levels of agreement among individual analytes, identifying binding…
  • Abstract Number: 0126 • ACR Convergence 2024

    Underdiagnosis Prediction Fingerprint for Antiphospholipid Syndrome Derived from Electronic Health Record Data

    Emily Balczewski1, Amala Ambati2, Wenying Liang1, Jacqueline Madison1, Yu Zuo1, Karandeep Singh3 and Jason Knight1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Toledo, OH, 3University of California -- San Diego, San Diego, CA

    Background/Purpose: Antiphospholipid syndrome (APS) is a rare autoimmune disease that is likely to demonstrate improved outcomes with earlier diagnosis and treatment. However, given APS’s complex,…
  • Abstract Number: 1556 • ACR Convergence 2024

    Efficacy and Safety of Anifrolumab Across Organ Domains of Systemic Lupus Erythematosus. A Systematic Review and Meta-Analysis

    Mohammad Taha1, Yomna W Mahmoud1, Mohammad Ramadan1, sarah nasir1, Mariam salah1, Yassin shenawy2, doaa gadelrab1 and Muhammad abuawwad1, and ARC team, 1Cairo university, Cairo, Egypt, 2cairo, cairo, Egypt

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems. Anifrolumab is a monoclonal antibody that antagonizes type I interferon receptors,…
  • Abstract Number: 0111 • ACR Convergence 2024

    Comparative Performance of ELISA and CLIA Against the 2023 ACR/EULAR APS Classification Criteria

    Polona Zigon1, Nika Bostič1, Ziga Rotar2, Ales Ambrozic3, Elizabeta Blokar3, Manca ogrič1 and Sasa Cucnik1, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, 3Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana

    Background/Purpose: Recently published 2023 ACR/EULAR APS classification criteria emphasize delineating moderate/high anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) antibodies. The new criteria specify the use…
  • Abstract Number: 0127 • ACR Convergence 2024

    Unsupervised Machine Learning Improves Clinical Stratification and Prognostic Evaluation for Antiphospholipid Syndrome: A Large Cohort Study from China

    Chen Chen1, Ao Zhang2, Jianhui Cheng3, Zhongqiang Yao4, Juan Meng5, Yilu Qin6, Qingyi Lu1, Yufei Li1, Xiangjun Liu1, Tianhao Li7, Chao Hou7, Yundi Tang1, Hongjiang Liu8, Ning Xu1, Sai Dong1, Xinxin Li3, Fangmin Xu2, Jianping Guo1 and Chun Li1, 1Peking University People's Hospital, Beijing, China, 2Beijing University of Posts and Telecommunications, Beijing, China, 3State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China (People's Republic), 4Peking University Third Hospital, Beijing, China, 5Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China, 6Affiliated Xinxiang Central Hospital of Xinxiang Medical University, Xinxiang, China (People's Republic), 7Peking University Health Science Center, Beijing, China, 8West China Hospital, Sichuan University, Chengdu, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is a complex disease characterized by the presence of anti-phospholipid antibodies (aPLs). Its significant clinical heterogeneity brings clinical and therapeutical challenges.…
  • Abstract Number: 1702 • ACR Convergence 2024

    Placental Developmental Defects in a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss

    Yunwei Xia1, Naomi I. Maria2, Zhengzi Yi3, Chirag Raparia4, Gayathri Konanur Gopikrishna1, Weijia Zhang3 and Anne Davidson2, 1Feinstein Institutes for Medical Research, Manhasset, 2Feinstein Institutes for Medical Research, Manhasset, NY, 3Mt. Sinai School of Medicine, New York, NY, 4Donald and Barbara Zucker School of Medicine At Hofstra/Northwell, Shoreham, NY

    Background/Purpose: Antiphospholipid antibodies (aPL) confer a high risk for adverse pregnancy outcomes, especially in women with SLE. aPLs can induce pro-inflammatory signaling via TLR8 receptors,…
  • Abstract Number: 0112 • ACR Convergence 2024

    Efforts to Harmonize ELISA and Non-ELISA Anticardiolipin and Anti-β2-glycoprotein-I Levels Based on ISTH SSC LA/aPL and APS ACTION International Multicenter Cohorts

    Arne Vandevelde1, Pierluigi Meroni2, Hannah Cohen3, Danieli Andrade4, Olga Amengual5, TATSUYA ATSUMI5, Angela Tincani6, H Michael Belmont7, Maria Borghi8, David Branch9, Ricard Cervera10, Guilherme Ramires de Jesús11, Paul Fortin12, Jean-Christophe Gris13, Claudia Grossi8, Jason Knight14, Gary W. Moore15, Jacek Musiał16, Michelle Petri17, Esther Rodriguez-Almaraz18, Diana Paredes-Ruiz19, Robert Roubey20, Anne Tebo21, Maria Tektonidou22, Denis WAHL23, Stéphane Zuily23, Rohan Willis24, Vittorio Pengo25, Maria Laura Bertolaccini26, Doruk Erkan27 and Katrien Devreese1, 1Department of Diagnostic Sciences, Ghent University and Coagulation Laboratory, Ghent University Hospital, Ghent, Belgium, 2IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 3University College London Hospitals NHS Foundation Trust, London, United Kingdom, 4University of São Paulo, São Paulo, SP, Brazil, 5Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 6ASST Spedali Civili-University of Brescia, Brescia, Italy, 7NYU School of Medicine, New York, NY, 8Immunorheumatology research laboratory, IRCCS Istituto Auxologico, Milan, Italy, 9University of Utah and Intermountain Healthcare, Salt Lake City, UT, 10Hospital Clinic de Barcelona, Barcelona, Spain, 11Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 12Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 13Department of Hematology, CHU Nîmes, Univ Montpellier, Nîmes, France and Department of Hematology, Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France and UMR UA11 INSERM IDESP - Montpellier University, France and Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 14University of Michigan, Ann Arbor, MI, 15Specialist Haemostasis Unit, Addenbrooke's Hospital, Cambridge, United Kingdom and Department of Natural Sciences, Middlesex University, London, United Kingdom, 16Department of Internal Medicine, Jagiellonian University Medical College, Kraków, Poland, 17Johns Hopkins University School of Medicine, Timonium, MD, 18Hospital Universitario 12 de Octubre, Madrid, Spain, 19Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, 20Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 21Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 22National and Kapodistrian University of Athens, Athens, Greece, 23Lorraine University, Nancy, France, 24University of Texas Medical Branch, Galveston, TX, 25Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 26King's College London, London, United Kingdom, 27Hospital for Special Surgery, New York, NY

    Background/Purpose: Correlation of numerical values between the low, moderate, and high (L, M,H) levels of enzyme-linked immunosorbent assay (ELISA) and non-ELISA platforms for anticardiolipin antibody…
  • Abstract Number: 0128 • ACR Convergence 2024

    Damage Index in Patients with Thrombotic Antiphospholipid Syndrome (DIAPS) Version 2.0: One Single Center Pilot Study

    Laura Aline Martinez-Martinez1, Mary-Carmen Amigo2 and María Victoria Goycochea Robles3, 1Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico, 2ABC Medical Center, Mexico City, Estado de México, Mexico, 3Universidad Nacional Autonoma de Mexico, Mexico city, Distrito Federal, Mexico

    Background/Purpose: Antiphospholipid antibody syndrome is the main acquired thrombophilia in the rheumatological area. It is characterized by thrombotic events and obstetric morbidity associated with the…
  • Abstract Number: 2374 • ACR Convergence 2024

    Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia

    Omer Uludag1, Sarvan Aghamuradov1, Cansu Erel Gezegen2, Marjan Jabbarli2, Ismat Habibov2, Ahmet Oguz Celik2, Yasemin Yalcinkaya1, Ahmet Gul1, Murat Inanc1 and Bahar Artim Esen1, 1Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey

    Background/Purpose: Thrombocytopenia has been reported at frequencies ranging from 10 to 40 % in different cohorts. Treatment can be challenging and due to its considerable…
  • 1
  • 2
  • 3
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology